Harmony Biosciences
HRMY
221 hedge funds and large institutions have $1.54B invested in Harmony Biosciences in 2023 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 62 increasing their positions, 77 reducing their positions, and 35 closing their positions.
215% more call options, than puts
Call options by funds: $5.6M | Put options by funds: $1.78M
57% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 35
8% more funds holding
Funds holding: 204 → 221 (+17)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0.54% less ownership
Funds ownership: 82.38% → 81.84% (-0.54%)
5% less capital invested
Capital invested by funds: $1.62B → $1.54B (-$78.1M)
19% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 77
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$34.2M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$20.9M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$14M |
| 4 |
Morgan Stanley
New York
|
+$9.23M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$6.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$36.8M |
| 2 |
PA
Perceptive Advisors
New York
|
-$32.6M |
| 3 |
NPIC
Neumeier Poma Investment Counsel
Carmel,
California
|
-$19.5M |
| 4 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
-$14.2M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$10.5M |
HRMY Hedge Fund Activity: Q4 2023 in Review
221 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q4 2023, worth a combined $1.54B — down 4.8% from $1.62B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new HRMY positions and 35 closed out — a net gain of 20 holders — while 62 added to existing stakes and 77 trimmed.
The largest buyer was Pacer Advisors, adding an estimated $34.2M. The largest seller was Adage Capital Partners, cutting an estimated $36.8M.
- 221 institutional investors held Harmony Biosciences (HRMY) as of Q4 2023, up from 204 in Q3 2023.
- Funds reported $1.54B of Harmony Biosciences stock for Q4 2023, down 4.8% quarter-over-quarter.
- 55 funds opened new Harmony Biosciences positions in Q4 2023 and 35 closed out, a net change of +20 holders.
- The largest Harmony Biosciences buyer in Q4 2023 was Pacer Advisors, an estimated $34.2M added.
- The largest Harmony Biosciences seller in Q4 2023 was Adage Capital Partners, an estimated $36.8M sold.
Based on aggregated 13F filings for Q4 2023.